Metoprolol is a lipophilic β1 selective adrenergic receptor antagonist used in antihypertensive therapy. It is metabolized by the protein product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the β1 adrenoreceptor, CYP2D6 polymorphism and blood pressure. The one reported here is a prospective, observational, clinical study in Chinese Han hypertensive patients on the combined influences of CYP2D6 and β1 adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension. The same dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 and β1 adrenoreceptor polymorphisms. Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and β1 adrenoreceptor polymorphisms. Knowledge of the combination of CYP2D6 and β1 adrenoreceptor polymorphisms may be used to guide antihypertensive therapy using β1 adrenoreceptor antagonists.
CowleyAWJr: The genetic dissection of essential hypertension. Nat Rev Genet2006; 7: 829–840.
2.
LalouelJM: Large-scale search for genes predisposing to essential hypertension. Am J Hypertens2003; 16: 163–166.
3.
LeeWKPadmanabhanSDominiczakAF: Genetics of hypertension: From experimental models to clinical applications. J Hum Hypertens2000; 14: 631–647.
4.
LiftonRPJeunemaitreX: Finding genes that cause human hypertension. J Hypertens1993; 11: 231–236.
5.
FuxRMörikeKPröhmerAM: Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clin Pharmacol Ther2005; 78: 378–387.
6.
LennardMSSilasJHFreestoneS: Oxidation phenotype–a major determinant of metoprolol metabolism and response. N Engl J Med1982; 307: 1558–1560.
7.
McGourtyJCSilasJHLennardMS: Metoprolol metabolism and debrisoquine oxidation polymorphism–population and family studies. Br J Clin Pharmacol1985; 20: 555–566.
8.
LennardMSTuckerGTWoodsHF: The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet1986; 11: 1–17.
9.
ZangerUMFischerJRaimundoS: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics2001; 11: 573–585.
10.
ZangerUMRaimundoSEichelbaumM: Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol2004; 369: 23–37.
11.
FreestoneSSilasJHLennardMS: Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol1982; 14: 713–718.
SandilandsAJO'ShaughnessyKM: The functional significance of genetic variation within the β1-adrenoceptor. Br J Clin Pharmacol2005; 60: 235–243.
16.
Revision Committee of the Chinese Guidelines on Prevention and Treatment of Hypertension: 2004 Chinese guidelines on prevention and treatment of hypertension. Chin J Hypertens2004; 12: 483–486 [in Chinese].
17.
MasonDAMooreJDGreenSA: A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem1999; 274: 12670–12674.
18.
TaguchiMNozawaTKameyamaT: Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol2003; 59: 385–388.
19.
LiggettSB: Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology2000; 61: 167–173.
20.
KirchheinerJHeeschCBauerS: Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther2004; 76: 302–312.
21.
LiuGZHuDYTaoP: Suggestions of evaluation method on clinical trial of cardiovascular medicines. Zhonghua Xin Xue Guan Bing Za Zhi1998; 26: 5–11.
22.
MotulskyAG: Drug reactions enzymes, and biochemical genetics. J Am Med Assoc1957; 165: 835–837.
23.
TurnerSTSchwartzGLChapmanAB: Antihypertensive pharmacogenetics: Getting the right drug into the right patient. J Hypertens2001; 19: 1–11.
24.
SookoianSGianottiTFGonzálezCD: Association of the C-344T aldosterone synthase gene variant with essential hypertension: A meta-analysis. J Hypertens2007; 25: 5–13.
25.
RegårdhCGJohnssonG: Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet1980; 5: 557–569.
26.
LiuJLiuZQTanZR: Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther2003; 74: 372–379.
27.
BengtssonKMelanderOMelanderM Orho: Polymorphism in the β1-adrenergic receptor gene and hypertension. Circulation2001; 104: 187–190.
28.
JohnsonJAZinehIPuckettBJ: β1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther2003; 74: 44–52.
29.
ZinehIBeitelsheesALGaedigkA: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther2004; 76: 536–544.
30.
LiuZQZhouHH: New era of individualized pharmacotherapy. Chin J Clin Pharmacol Ther2007; 12: 1–6.
